An observational study in COPD, sponsored by University Medical Center Groningen. Recruiting at 4 sites in Netherlands. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by University Medical Center Groningen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen — 6 open to participants now, 6 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University Medical Center Groningen.
Among the 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2025, is one of 14 observational ones, and was the 28th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →6 of the 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen are open now, in 4 countries. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Czechia, Denmark, Netherlands and 1 more country
Ages 18+
University Medical Center Groningen · Sites in Netherlands
University Medical Center Groningen · Sites in Netherlands
Ages 40+
University Medical Center Groningen · Sites in Netherlands
University Medical Center Groningen · Sites in Netherlands
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 28 across the 14 interventional studies, 60 across the 14 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 175 are open to participants now.
3 of the studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05938738University Medical Center GroningenPEP-buddy in COPD: Effect on Dyspnea Severity and Mechanism of Action | 2026-12-31 |
| NCT06782724University Medical Center GroningenPsilocybin Therapy for Psychological Distress in Palliative Patients | 2027-01-01 |
| NCT04214587University Medical Center GroningenBiological Investigation of Explanted Endobronchial Lung Valves Study | 2027-03-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Rationale: In patients with chronic lung diseases, the role of respiratory muscle dysfunction has been underestimated. Also, current treatment options, like chronic NIV and lung transplantation (LTx), might also have deleterious effects on the respiratory muscles, and the mechanisms are poorly understood.
Therefore in this exploratory study the objectives are to:
Study design: The study will be an exploratory observational cohort study following patients on the LTx waiting list during the waiting period and afterwards until they showed functional recovery of respiratory muscle function.
Study population: Adult COPD patients on the LTx waiting list will be included. Intervention (if applicable): None
Main study parameters/endpoints:
To assess clinical functioning of the respiratory muscles we will assess respiratory electrical activity as a measure of respiratory effort by surface EMG, and thickening fraction of the diaphragm and intercostal muscles and diaphragm excursions by ultrasound and maximal in- and expiratory pressure to assess muscle output; all before and after LTx. We will relate and correct these data for hyperinflation and degree of lung damage by using data from standard care lung function tests and CT scans, and will relate these measurements to prior treatment (NIV settings) and outcome after LTx, by retrieving these data from the EPD.
To assess contractility of respiratory myofibers and in vivo respiratory muscle function, biopsies will be taken during LTx surgery and the biopsies will be analyzed in the lab of Prof. Ottenheijm (AmsterdamUMC) for individual myofiber functioning (strength, calcium sensitivity, myofiber characteristics) and in the lab of Dr. Pouwels for extracellular matrix characteristics.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Overall, risks are believed to be minimal. The clinical measurements are non-invasive and/or regular performed in clinical practice. Also, we decided to do those measurements during regular control visits, limiting the burden for the patients. Taking biopsies from the respiratory muscles during surgery has been extensively performed without any risk; the biobank of the Ottenheijm group contains > 500 samples and never any complication has been observed. Also, in preparation of the present study we performed a pilot study in 12 COPD patients of whom.. biopsies were taken at the UMCG without side effects or complications. The biopsies will be done with the patients being under full anesthesia, so participants will feel no discomfort.
Considering that a) there is a substantial proportion of patients with severe COPD that develop respiratory muscle dysfunction-induced CHRF; b) respiratory pump failure results in significant morbidity and mortality; and c) the response to current treatment options is highly variable, presumably due to detrimental effects on the respiratory muscle pump, there is a high need for research identifying the pathophysiological mechanisms that underlie respiratory muscle dysfunction in end stage COPD. To meet this need, we will combine in vivo respiratory muscle testing with studies on unique respiratory muscle biopsies to test the hypothesis that respiratory muscle dysfunction is caused by atrophy and reduced contractility of single respiratory myofibers, and that this underlies the development of CHRF. Furthermore, we will test the hypothesis that respiratory muscle dysfunction is exacerbated by NIV and contributes to difficulties in post-LTx recovery. The outcomes will identify targets for intervention and prevention of CHRF.
COPD patients on the lung transplantation waiting list
In order to be eligible to participate in this study, a participant must meet all of the following criteria:
A potential participant who meets any of the following criteria will be excluded from participation in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group of patients on nocturnal NIV prior to LTx
Group of patients who are chronic hypercapnic but not on NIV prior to LTx
Group of normocapnic patients prior to LTx
Respiratory neural drive
With surface EMg (sEMG) a measure of respiratory neural drive is obtained, which could be used as stand alone parameter to estimate effort and, when combined with output parameters as diaphragm movement or MIP/MEP, might be useful to estimate neuro-ventilatory efficiency.
Time frame: 3-6 monthly before LTx, directly before and after LTx, 3-6 monthly after LTx
Respriatory muscle output - contraction and movement
With ultrasound, we will measure diaphragm and intercostal thickening fraction (DF-TF) thereby investigating the amount of muscle contraction. Diaphragm excursion will be measured from subcostally.
Time frame: 3-6 monthly before LTx, directly before and after LTx, 3-6 monthly after LTx
Respriatory muscle output - strength
Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) will be measured at the lung function department according to ERS guidelines or by using a handheld device when patients are at the ward. Patients are asked to inhale and exhale deeply against a resistance and then measuring airway pressure produced.
Time frame: 3-6 monthly before LTx, directly before and after LTx, 3-6 monthly after LTx
Myofiber mechanics
The maximum force generating capacity, the force response to a range of submaximal \[Ca2+\], active stiffness (reflecting the number of attached and non-attached myosin heads) is determined of individual myofibers.
Time frame: Biopsies are obtained during LTx
Low angle X-ray diffraction
Measure the position of myosin heads in relaxed and in activated myofibers
Time frame: Biopsies are obtained during LTx
Mant-ATP chase experiments
To biochemically assess the percentage of myosin heads in the SRX state
Time frame: Biopsies are obtained during LTx
Myofiber and extra-cellular matrix structure
We will assess myofiber size by immunohistochemistry using antibodies that label the sarcolemma and myosin heavy chain isoforms
Time frame: Biopsies are obtained during LTx
Transcriptomic and proteomic analyses of muscle biopsies
To study the activation of fibrosis pathways we will apply RNAseq and proteomics on the biopsies
Time frame: Biopsies are obtained during LTx
Plan to share: No — With such a specific group it is too difficult to keep it anonomyzed
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Apr 2029, 43 months after the start.
Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 43 months is above that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
University Medical Center Groningen →